CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a German speaking press conference on the same day at 02:00 p.m. CEST / 08:00 a.m. EST.

Please find the corresponding press release, presentation slides and archived webcast below.